Kumar Devinder, Ghoshal Uday C, Saigal Vamika Mansi, Chaudhary Moni, Sahu Shikha, Pandya Vishruti, Ghoshal Ujjala
St George's University of London London UK.
Department of Surgery Apollo Hospital Ahmedabad India.
JGH Open. 2025 Jun 29;9(7):e70211. doi: 10.1002/jgh3.70211. eCollection 2025 Jul.
Less than half of all patients with Crohn's disease remain in remission with long-term use of azathioprine. Our aim was to assess the efficacy of Artesunate and Curcumin in maintaining remission in patients with Crohn's disease, who had ongoing evidence of disease activity despite taking azathioprine.
Patients with Crohn's disease being treated with azathioprine for at least 3 months but still had mild to moderate Crohn's disease (CDAI 150-450) were included. Patients were randomized into four blocks of 10 patients each in a 2 × 2 factorial design to receive artesunate 200 mg PO daily for 2 weeks and/or curcumin 200 mg PO daily for 3 months or placebo. Harvey-Bradshaw Index, CDAI, and fecal calprotectin were measured at baseline, 1 week, 1 month, 3 months, and 6 months.
Forty patients were recruited and randomized into the study. Both Artesunate and Curcumin were well tolerated with no adverse effects. The Harvey-Bradshaw Index statistically differed across the treatment groups at 6 months ( = 0.047), there were no significant group differences in the post hoc pairwise analysis. The differences in CDAI from baseline to 6 months were statistically significant in Artesunate + Curcumin ( = 0.0098) and Curcumin + Placebo ( = 0.0431) groups. Similarly, statistically significant differences were observed between Baseline and 6 months for the Harvey-Bradshaw Index in the Artesunate + Curcumin ( = 0.0070) and Curcumin + Placebo ( = 0.0138) groups.
A combination of artesunate and curcumin in patients with ongoing inflammatory activity appears to be effective as measured by CDAI and Harvey-Bradshaw Index.
长期使用硫唑嘌呤治疗的克罗恩病患者中，缓解的患者不到半数。我们的目的是评估青蒿琥酯和姜黄素对克罗恩病患者维持缓解的疗效，这些患者尽管服用了硫唑嘌呤，但仍有疾病活动的证据。
纳入正在接受硫唑嘌呤治疗至少3个月但仍患有轻至中度克罗恩病（CDAI 150 - 450）的患者。患者按2×2析因设计随机分为4个区组，每组10例，分别接受青蒿琥酯200mg口服，每日1次，共2周和/或姜黄素200mg口服，每日1次，共3个月，或安慰剂。在基线、1周、1个月、3个月和6个月时测量哈维 - 布拉德肖指数、CDAI和粪便钙卫蛋白。
招募了40例患者并随机分组进入研究。青蒿琥酯和姜黄素耐受性良好，无不良反应。6个月时，各治疗组的哈维 - 布拉德肖指数在统计学上有差异（= 0.047），事后两两分析中无显著组间差异。青蒿琥酯 + 姜黄素组（= 0.0098）和姜黄素 + 安慰剂组（= 0.0431）从基线到6个月的CDAI差异有统计学意义。同样，青蒿琥酯 + 姜黄素组（= 0.0070）和姜黄素 + 安慰剂组（= 0.0138）在基线和6个月时哈维 - 布拉德肖指数有统计学显著差异。
以CDAI和哈维 - 布拉德肖指数衡量，青蒿琥酯和姜黄素联合使用对仍有炎症活动的患者似乎有效。
